158 related articles for article (PubMed ID: 32680922)
1. Fluorescence-Guided Visualization of Soft-Tissue Sarcomas by Targeting Vascular Endothelial Growth Factor A: A Phase 1 Single-Center Clinical Trial.
Steinkamp PJ; Pranger BK; Li MF; Linssen MD; Voskuil FJ; Been LB; van Leeuwen BL; Suurmeijer AJH; Nagengast WB; Kruijff S; van Ginkel RJ; van Dam GM
J Nucl Med; 2021 Mar; 62(3):342-347. PubMed ID: 32680922
[TBL] [Abstract][Full Text] [Related]
2. Back-Table Fluorescence-Guided Imaging for Circumferential Resection Margin Evaluation Using Bevacizumab-800CW in Patients with Locally Advanced Rectal Cancer.
de Jongh SJ; Tjalma JJJ; Koller M; Linssen MD; Vonk J; Dobosz M; Jorritsma-Smit A; Kleibeuker JH; Hospers GAP; Havenga K; Hemmer PHJ; Karrenbeld A; van Dam GM; van Etten B; Nagengast WB
J Nucl Med; 2020 May; 61(5):655-661. PubMed ID: 31628218
[TBL] [Abstract][Full Text] [Related]
3. Intraoperative Molecular Fluorescence Imaging of Pancreatic Cancer by Targeting Vascular Endothelial Growth Factor: A Multicenter Feasibility Dose-Escalation Study.
Mulder BGS; Koller M; Duiker EW; Sarasqueta AF; Burggraaf J; Meijer VE; Vahrmeijer AL; Hoogwater FJH; Bonsing BA; van Dam GM; Mieog JSD; Pranger BK
J Nucl Med; 2023 Jan; 64(1):82-89. PubMed ID: 35680414
[TBL] [Abstract][Full Text] [Related]
4. Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial.
Vergeer RA; Postma MR; Schmidt I; Korsten-Meijer AG; Feijen RA; Kruijff S; Nagengast WB; van Dijk JMC; den Dunnen WFA; van Beek AP; Kuijlen JMA; van den Berg G
BMJ Open; 2021 Oct; 11(10):e049109. PubMed ID: 34620658
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.
Voskuil FJ; de Jongh SJ; Hooghiemstra WTR; Linssen MD; Steinkamp PJ; de Visscher SAHJ; Schepman KP; Elias SG; Meersma GJ; Jonker PKC; Doff JJ; Jorritsma-Smit A; Nagengast WB; van der Vegt B; Robinson DJ; van Dam GM; Witjes MJH
Theranostics; 2020; 10(9):3994-4005. PubMed ID: 32226534
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence grid analysis for the evaluation of piecemeal surgery in sinonasal inverted papilloma: a proof-of-concept study.
Vonk J; Voskuil FJ; de Wit JG; Heeman WT; Nagengast WB; van Dam GM; Feijen RA; Korsten-Meijer A; van der Vegt B; Witjes M
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1640-1649. PubMed ID: 34738141
[TBL] [Abstract][Full Text] [Related]
7. Molecular Fluorescence Endoscopy Targeting Vascular Endothelial Growth Factor A for Improved Colorectal Polyp Detection.
Tjalma JJ; Garcia-Allende PB; Hartmans E; Terwisscha van Scheltinga AG; Boersma-van Ek W; Glatz J; Koch M; van Herwaarden YJ; Bisseling TM; Nagtegaal ID; Timmer-Bosscha H; Koornstra JJ; Karrenbeld A; Kleibeuker JH; van Dam GM; Ntziachristos V; Nagengast WB
J Nucl Med; 2016 Mar; 57(3):480-5. PubMed ID: 26678613
[TBL] [Abstract][Full Text] [Related]
8. Preclinical imaging of epidermal growth factor receptor with ABY-029 in soft-tissue sarcoma for fluorescence-guided surgery and tumor detection.
Samkoe KS; Sardar HS; Bates BD; Tselepidakis NN; Gunn JR; Hoffer-Hawlik KA; Feldwisch J; Pogue BW; Paulsen KD; Henderson ER
J Surg Oncol; 2019 Jun; 119(8):1077-1086. PubMed ID: 30950072
[TBL] [Abstract][Full Text] [Related]
9. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study.
Harlaar NJ; Koller M; de Jongh SJ; van Leeuwen BL; Hemmer PH; Kruijff S; van Ginkel RJ; Been LB; de Jong JS; Kats-Ugurlu G; Linssen MD; Jorritsma-Smit A; van Oosten M; Nagengast WB; Ntziachristos V; van Dam GM
Lancet Gastroenterol Hepatol; 2016 Dec; 1(4):283-290. PubMed ID: 28404198
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW.
Huisman LA; Steinkamp PJ; Hillebrands JL; Zeebregts CJ; Linssen MD; Jorritsma-Smit A; Slart RHJA; van Dam GM; Boersma HH
Sci Rep; 2021 Feb; 11(1):2899. PubMed ID: 33536498
[TBL] [Abstract][Full Text] [Related]
11. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
Terwisscha van Scheltinga AG; van Dam GM; Nagengast WB; Ntziachristos V; Hollema H; Herek JL; Schröder CP; Kosterink JG; Lub-de Hoog MN; de Vries EG
J Nucl Med; 2011 Nov; 52(11):1778-85. PubMed ID: 21990576
[TBL] [Abstract][Full Text] [Related]
12. Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW.
Warram JM; de Boer E; Korb M; Hartman Y; Kovar J; Markert JM; Gillespie GY; Rosenthal EL
Br J Neurosurg; 2015; 29(6):850-8. PubMed ID: 26073144
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of fluorescence-guided surgery agents in a murine model of soft tissue fibrosarcoma.
Prince AC; McGee AS; Siegel H; Rosenthal EL; Behnke NK; Warram JM
J Surg Oncol; 2018 May; 117(6):1179-1187. PubMed ID: 29284070
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of a connective tissue phantom model for subsurface visualization of cancers requiring wide local excision.
Samkoe KS; Bates BD; Tselepidakis NN; DSouza AV; Gunn JR; Ramkumar DB; Paulsen KD; Pogue BW; Henderson ER
J Biomed Opt; 2017 Dec; 22(12):1-12. PubMed ID: 29274143
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Specific Imaging with Angiostamp800 or Bevacizumab-IRDye 800CW Improves Fluorescence-Guided Surgery over Indocyanine Green in Peritoneal Carcinomatosis.
Josserand V; Bernard C; Michy T; Guidetti M; Vollaire J; Coll JL; Hurbin A
Biomedicines; 2022 May; 10(5):. PubMed ID: 35625796
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of bevacizumab-IRDye800CW as a tracer for fluorescence-guided meningioma surgery.
Dijkstra BM; Nonnekens J; Nagengast W; Kruijff S; Meersma GJ; den Dunnen WFA; Kruyt FAE; Groen RJM
J Neurosurg; 2023 May; 138(5):1263-1272. PubMed ID: 36308486
[TBL] [Abstract][Full Text] [Related]
17. Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.
Lamberts LE; Koch M; de Jong JS; Adams ALL; Glatz J; Kranendonk MEG; Terwisscha van Scheltinga AGT; Jansen L; de Vries J; Lub-de Hooge MN; Schröder CP; Jorritsma-Smit A; Linssen MD; de Boer E; van der Vegt B; Nagengast WB; Elias SG; Oliveira S; Witkamp AJ; Mali WPTM; Van der Wall E; van Diest PJ; de Vries EGE; Ntziachristos V; van Dam GM
Clin Cancer Res; 2017 Jun; 23(11):2730-2741. PubMed ID: 28119364
[No Abstract] [Full Text] [Related]
18. Targeting tumors with a killer-reporter adenovirus for curative fluorescence-guided surgery of soft-tissue sarcoma.
Yano S; Miwa S; Kishimoto H; Uehara F; Tazawa H; Toneri M; Hiroshima Y; Yamamoto M; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
Oncotarget; 2015 May; 6(15):13133-48. PubMed ID: 26033451
[TBL] [Abstract][Full Text] [Related]
19. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.
Kambadakone A; Yoon SS; Kim TM; Karl DL; Duda DG; DeLaney TF; Sahani DV
AJR Am J Roentgenol; 2015 Jan; 204(1):W11-8. PubMed ID: 25539263
[TBL] [Abstract][Full Text] [Related]
20. Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent.
Hoogstins CES; Boogerd LSF; Sibinga Mulder BG; Mieog JSD; Swijnenburg RJ; van de Velde CJH; Farina Sarasqueta A; Bonsing BA; Framery B; Pèlegrin A; Gutowski M; Cailler F; Burggraaf J; Vahrmeijer AL
Ann Surg Oncol; 2018 Oct; 25(11):3350-3357. PubMed ID: 30051369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
